ArticleAnnals of gastroenterological surgery2026
Clinical Significance of Copper Chaperone for Superoxide Dismutase in Colorectal Cancer.
Article in Annals of gastroenterological surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Targeting Cu transport proteins is an innovative therapeutic approach for combating cancer. However, the mechanisms underlying the malignant potential of Cu transport proteins remain largely unknown. To address this issue, we focused on the oncogenic potential of copper chaperones for superoxide dismutase (CCS) in colorectal cancer (CRC). Methods: We investigated the association between the prognosis and the copper transport protein, CCS, using clinical samples. The function of CCS was analyzed to assess the proliferation and migration potential of CRC cells. Results: Univariate and multivariate analyses revealed that CCS was an independent prognostic factor for disease-free survival and overall survival. CCS is closely related to the malignant potential of CRC, which includes proliferation, migration, and the MEK-ERK pathway. Conclusions: Thus, CCS is a valuable biomarker and therapeutic target for CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.